
1. j antimicrob chemother. 2009 jun;63(6):1251-5. doi: 10.1093/jac/dkp114. epub 2009
mar 31.

virological immunological response hiv-1-infected patients multiple
treatment failures receiving raltegravir optimized background therapy, anrs
co3 aquitaine cohort.

wittkop l(1), breilh d, da silva d, duffau p, mercié p, raymond i, anies g,
fleury h, saux mc, dabis f, fagard c, thiébaut r, masquelier b, pellegrin i; anrs
co3 aquitaine cohort.

collaborators: dabis f, dupon m, longy-boursier m, morlat p, pellegrin jl,
ragnaud jm, bruyand m, chéne g, dabis f, lawson-ayayi s, thiébaut r, bonarek m,
bonnal f, bonnet f, bernard n, caubet o, caunégre l, cazanave c, ceccaldi j,
dauchy fa, de la taille c, de witte s, dupon m, duffau p, dutronc h, farbos s,
gemain mc, greib c, lacoste d, lafarie-castet s, loste p, malvy d, mercié p,
morlat p, neau d, ochoa a, pellegrin jl, ragnaud jm, tchamgoué s, viallard jf,
blanco p, moreau jf, pellegrin i, fleury h, lafon me, masquelier b, breilh d,
miremont-salamé g, blaizeau mj, decoin m, delveaux s, gillet s, hannapier c,
leleux o, uwamaliya-nziyumvira b, geffard s, palmer g, touchard d.

author information: 
(1)inserm, unit epidemiology biostatistics, bordeaux, france.
linda.wittkop@isped.u-bordeaux2.fr

background: efficacy raltegravir plus optimized background therapy (obt)
has demonstrated antiretroviral (arv)-experienced hiv-1-infected
patients randomized clinical trials. studied viro-immunological response,
pharmacokinetic parameters genotypic test results observational cohort 
of multiple arv class-experienced patients starting raltegravir-based regimen.
methods: already enrolled anrs co3 aquitaine cohort patients virological
failure included study starting raltegravir-based regimen
(400 mg twice day, week 0). virological success defined plasma hiv-1
rna level [viral load (vl)] <2.7 log(10) copies/ml week 12 <1.7 log(10)
copies/ml week 24. one patient excluded analysis (no
follow-up week 4).
results: fifty-one patients [male/female = 43/8, median age = 48 (interquartile
range = 43, 55) years] included. week 0, median cd4 count 244 (110;
310)/mm(3) median vl 4.2 (3.6, 4.7) log(10) copies/ml. week 24, 39
(78%) patients experienced virological success: 4 (44%), 14 (82%) 21 (87%)
patients genotypic sensitivity score <1, > =1 <2 > =2 (p =
0.02), respectively. raltegravir-related mutations emerged 9 11 failing
patients (82%): q148h/r (n = 5), n155s/h (n = 3) s230n (n = 1). median cd4
increases week 0 week 4 week 24 28 (-4, 85) 57 (0, 156)
cells/mm(3), respectively. poor immune response independently associated
with lower vl decline (week 0 week 12) [odds ratio (or): 3.5, 95% confidence
interval (ci): 1.4, 8.4, 1 log(10) less] cd4+% baseline (or: 2.6, 95% 
ci: 0.97, 8.3, 10% lower).
conclusions: raltegravir plus obt provided good virological success rate in
highly pre-treated patients clinical routine conditions.

doi: 10.1093/jac/dkp114 
pmcid: pmc2885067
pmid: 19336453  [indexed medline]

